Date: 2014-05-21
Type of information: Nomination
Compound: member of the board of directors
Company: Nuevolution (Denmark)
Therapeutic area: Technology - Services
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 21, 2014, Nuevolution announced that Dr. Brian Zambrowicz, Ph.D has joined Nuevolution as Director and Senior Scientific Advisor to the Board of Directors. Brian Zambrowicz, Ph.D. is one of the co-founders of Lexicon Pharmaceuticals Inc. and has served the company as Executive Vice President and Chief Scientific Officer since 2007. Dr. Zambrowicz has been instrumental in setting the overall scientific direction of the company, including the development of Lexicon’s proprietary gene knockout technology and small molecule drug discovery pipeline. Under his direction, Lexicon has knocked out and analyzed nearly 5,000 genes resulting in the identification of more than 100 potential new drug targets. He has been involved in the discovery and development of Lexicon’s portfolio of clinical stage programs, including LX4211, a dual SGLT1 and SGLT2 inhibitor for Type 1 and 2 diabetes, and telotristat etiprate for carcinoid syndrome. Prior to joining Lexicon, he served as a National Institutes of Health postdoctoral fellow at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Dr. Zambrowicz received his B.S. in biochemistry from the University of Wisconsin, Madison and his Ph.D. in biochemistry from the University of Washington, Seattle.
- Nuevolutions Board of Directors is composed as follows:
- Stig Løkke Pedersen, Chairman of the Board.
Viktor Drvota, Director, SEB Venture Capital, Head of Investment Area, Life Science.
Søren Lemonius, Director, Partner, Sunstone Capital.
Jonas Brambeck, Director, Investment Manager, Industrifonden.
Professor Dr. Jutta Heim, Director, Senior Scientific Advisor to the Board
Dr. Brian Zambrowicz, Director, Senior Scientific Advisor to the Board
Stefan Olofsson, Observer, SEB Venture Capital Investment Manager, Life Science and Technology.
Financial terms:
Latest news:
Is general: Yes
